BioSpace

UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years

The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.

作者 BioSpace

1 分钟阅读
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察